C22.0
Conditions
Interventions
Group 1: After the patient has consented to the study, certain blood tests will be performed for therapy planning and early detection.
Brachytherapies will be performed as part of the clinical standar
Sponsors
Klinikum der Universität München, Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: a) treatment naïve HCC patients, BCLC 0 or A, maximum size of lesions <3cm b) male/female, =18 c) indication for thermoablation d) indication for TA according to multidisciplinary board decision e) informed consent signed
Exclusion criteria
Exclusion criteria: a) age <18 b) other pre-existing malignancies c) contraindication for resection or thermoablation d) life expectation < 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of tumor cells and tumor genetic information in blood before and after therapy in HCC disease. Time to progression (local or de novo) and the change in - circulating tumor cells before and after brachytherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The depiction of immuno-phenotypes of tissues adjacent to TA intervention areas - Correlation of HCC precursor lesions in baseline imaging and post ablation CTC burden | — |
Countries
Germany
Contacts
Public ContactMonika Dienst
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
Outcome results
None listed